Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Pfizer’s Methotrexate 1000 mg Hit by Stock-Out on Flaws at German Manufacturing Site
Pfizer Japan has exhausted its inventory of Methotrexate Injection 1000 mg due to a temporary manufacturing halt at its German production site caused by flawed testing. This has triggered a shipment control for the drug’s 200 mg version in Japan,…
To read the full story
Related Article
- Shipment Control Lifted for Pfizer's Methotrexate Injection After One Year
January 21, 2022
- Pfizer Japan Mulls Over Alternative Manufacturing Route Following Suspension of Methotrexate Production in Germany
April 19, 2019
- Patient Groups Press for Emergency Import of Methotrexate amid Tight Supply
April 8, 2019
BUSINESS
- Suntory to Acquire Daiichi Sankyo’s OTC Business for 246.5 Billion Yen
April 16, 2026
- MSD Debuts HIV Drug Idvynso in Japan in World-First Launch
April 16, 2026
- GSK’s Long-Acting Asthma Drug Exdensur Now Available in Japan
April 16, 2026
- Asahi Kasei Confident of Hitting 2027 Profit Goal, Tarpeyo as Pharma Growth Driver
April 16, 2026
- Sanwa Files Paltusotine in Japan for Acromegaly, Pituitary Gigantism
April 16, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…